Researchers at Beth Israel Deaconess Medical Center and Harvard Medical School have worked together to create an analysis of breast cancer pathology that incorporates artificial intelligence. They found that their system--and the evaluation by pathologists themselves--worked better when used in conjunction than either did alone.
Langer startup reports data, starts pivotal trial for bioengineered blood vessel for dialysis patients
Bioengineered blood vessels could see an early use aiding hemodialysis patients who have exhausted their vascular access options.
The Goldman Sachs-backed startup Imaging Advantage, which reportedly tapped into up to $250 million in debt in January 2015, has partnered with the Massachusetts Institute of Technology as well as Harvard Medical School and Massachusetts General Hospital to develop an artificial intelligence engine known as Singularity Healthcare.
Pancreatic cancer is usually treated with intravenous chemotherapy, but these injections often fail because the pancreas lies so deep within the abdomen. Now researchers from MIT and Massachusetts General Hospital have developed a minimally invasive implantable device that delivers chemo drugs directly to pancreatic tumors.
An MIT team has invented a device that makes a variety of drugs "on demand."
Researchers at MIT have discovered a new way to deliver targeted drugs to a specific target. By attaching a polymer drug-loaded target to a white blood cell, they can hitch a ride to sites in the body where drugs are needed and release the payload there.
Gecko Biomedical has raised €22.5 million ($25.5 million) to get it through the clinic and gain regulatory approval for its biopolymer platform in several indications for tissue reconstruction. It's aiming for a first approval within a year--with the first focus on its cardiovascular reconstruction candidate, dubbed GB-02. The goal is to create an entire product portfolio based on its novel polymer that enables guided tissue repair and localized drug delivery.
The National Institutes of Health has launched a program to explore the role of genomics in common diseases such as heart disease, diabetes, stroke and autism. This program has gained a commitment for $313 million in NIH funding from various agencies over the next four years.
Researchers hope to be in proof-of-concept clinical trials within the next 5 years on brain implants that will create an artificial pathway between the brain and paralyzed limbs. The expectation is that this kind of technology is expected to offer a means to circumvent paralysis that is due to damage to the nervous system that cuts off signals from the brain.
Massachusetts Institute of Technology researchers have published an animal proof-of-concept study of their ingestible vital sign monitor that tracks heart and respiratory rates in real time.